| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | -100.0% |
| Cost of Revenue | $0 | — | -100.0% |
| Gross Profit | $0 | — | — |
| R&D Expense | $1.6M | +8.1% | +11.2% |
| SG&A Expense | $122K | +18.4% | +96.8% |
| Operating Income | -$3.3M | -22.0% | -7.8% |
| Net Income | -$3.2M | -20.5% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $8.6M | -21.0% | +24.0% |
| Accounts Receivable | $0 | — | -100.0% |
| Current Assets | $17.0M | -11.9% | +131.7% |
| Total Assets | $17.4M | -11.5% | +124.9% |
| Current Liabilities | $1.6M | -14.8% | +41.4% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$5.5M | — | — |
| Capital Expenditures | $80K | — | — |
| Investing Cash Flow | -$80K | — | — |
| Financing Cash Flow | $13.5M | — | — |
| Free Cash Flow | -$5.6M | — | — |
| -5.9% |
| EPS (Basic) | $0.07 | +16.7% | -12.5% |
| EPS (Diluted) | $0.07 | +16.7% | -12.5% |
| $2.2M |
| -9.9% |
| +68.6% |
| Stockholders' Equity | $15.2M | -11.7% | +136.1% |